Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Sanofi teams up with U.S. agency against coronavirus

02/18/2020 | 11:42am EST
Sanofi annual results news conference in Paris

French drugmaker Sanofi is working with a U.S. government agency to develop a vaccine against the new coronavirus from China, saying it could have a candidate ready for clinical trials within a year.

At least a dozen other drugmakers are currently working on vaccines or antivirals and other treatments to help those infected with the fast-spreading deadly virus, with some antivirals already being used in clinical trials.

Sanofi said on Tuesday it had teamed up with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Health Department.

It intends to further investigate an advanced pre-clinical vaccine candidate previously developed against the SARS virus in the early 2000s, which it believes could protect against the latest coronavirus.

Financial details of the partnership were not disclosed.

"We are calculating that we are going to have a vaccine candidate available for in vitro testing within less than six months and potentially enter clinical trials within a year or a year and a half," David Loew, Sanofi's global head of vaccines, told journalists.

Loew said Sanofi would operate a DNA platform it already uses for the development of vaccines to treat the flu, a disease for which the company has a well-established expertise.

To move vaccine candidates from the lab to widespread use in patients involves a number of hurdles, according to health experts and executives for drugmakers working on coronavirus vaccines and treatments.

In addition to scaling up manufacturing capacity and building distribution networks, there are regulatory obstacles such as conducting large clinical trials to make sure a vaccine not only confers immunity to the virus but is safe for use in the general population.

Johnson & Johnson on Tuesday said it will work with the BARDA to look for potential antiviral drugs for the coronavirus, expanding on a partnership it announced last week to develop a vaccine against the outbreak.

China reported on Tuesday its fewest new coronavirus infections since January and its lowest daily death toll for a week, but the World Health Organization said data suggesting the epidemic had slowed should still be viewed with caution.

(Reporting by Matthias Blamont, additional reporting by Manas Mishra in Bengaluru; Editing by Sarah White, Susan Fenton and Shailesh Kuber)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
DNA OYJ 0.00%End-of-day quote.-0.10%
SANOFI -1.13% 81.42 Real-time Quote.4.64%
TELENOR ASA -1.22% 145.85 Real-time Quote.1.20%
Latest news "Companies"
05:59pEVERFUEL A/S : NOK 600 million private placement successfully completed
AQ
05:58pTHE LAW OFFICES OF FRANK R. CRUZ : Announces the Filing of a Securities Class Action on Behalf of Lizhi, Inc. (LIZI) Investors
BU
05:56pBANCO PINE S A : 01/21/2021 - Material Fact - Swap Transaction
PU
05:56pBANCO BRADESCO S A : Reference Form 2020
PU
05:52p‘CHEMICALS OUTLOOK 2021 : The Worst Is Over, But the Challenges Remain'
PU
05:52pFORTESCUE METALS : Dr Andrew Forrest Boyer Lecture
PU
05:52pCISCO : Role in the Monumental Vaccination Effort
PU
05:50pASTRAZENECA : Brazil announces incoming vaccine cargo amid supply concerns
AQ
05:50pCongressman Alex X. Mooney Statement on Biden's Day One Executive Orders
PU
05:50pPG&E : 2020 Safety Certificate
PU
Latest news "Companies"